Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Perforated Appendicitis and Postoperative Antibiotics Pilot Trial (PAPA Pilot)

The goal of this clinical trial is to learn if not giving antibiotics is as effective as giving antibiotics after surgery for patients who have surgery for a perforated (burst) appendix. This pilot study will also help determine whether a larger, multi-centre study can be successfully conducted. The main questions it aims to answer are:

  • Do patients who do not receive antibiotics after surgery have similar rates of infection after surgery as patients who do?
  • Is it feasible to enroll and randomize patients and collect complete health data for a larger multi-centre study?

Researchers will compare patients who do not receive antibiotics after surgery to patients who do to see whether avoiding antibiotics is as effective as using antibiotics for preventing infections after surgery.

Participants will:

  • Be randomly assigned to either receive or not receive antibiotics after surgery for their perforated (burst) appendix.
  • Be contacted 30 and 90 days after surgery to check for infections and other health outcomes.

Studieoversikt

Detaljert beskrivelse

Acute appendicitis, a sudden and severe inflammation of the appendix, is the most common emergency general surgery condition worldwide. In some cases, the appendix perforates, leading to contamination or infection within the abdominal cavity. Complicated appendicitis is associated with higher morbidity and mortality, including a higher risk of surgical site infections (SSIs). Approximately 20% of patients with complicated appendicitis develop an SSI, compared to about 5% of patients with uncomplicated appendicitis.

The use of antibiotics before surgery is well established and standard practice to reduce SSI risk. However, there is limited evidence to guide the use of antibiotics after surgery in patients with complicated appendicitis. Antibiotics carry potential risks, including allergic reactions, gastrointestinal side effects, and secondary infections, and their overuse contributes to antimicrobial resistance, which is a growing global health concern. As a result, there is a considerable variation in clinical practice, with some surgeons routinely prescribing post-operative antibiotics and others choosing not to.

Large, high-quality randomized controlled trials (RCTs), the gold-standard in clinical research, are needed to understand if post-operative antibiotics are necessary in this population. The current study will evaluate the impact of post-operative antibiotics on SSIs in patients with perforated appendicitis. This pilot specifically aims to determine the feasibility of a larger, multi-centre RCT, and will assess our ability to enroll and randomize patients, and to collect complete health data using an existing framework. Patients will be randomly assigned to receive post-operative antibiotics or no post-operative antibiotics after surgery for perforated appendicitis, and will be followed until 30 days after surgery to assess incidence of SSIs, with additional outcomes collected up to 90 days post-surgery.

Studietype

Intervensjonell

Registrering (Antatt)

100

Fase

  • Ikke aktuelt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Adults aged 18 years or older
  • Scheduled to undergo an open or laparoscopic appendectomy
  • Complicated appendicitis confirmed intra-operatively (AAST Appendicitis Grade III or IV)

Exclusion Criteria:

  • Patients demonstrating signs of septic shock for whom the omission of systemic antibiotics is contraindicated
  • Patients with positive blood cultures for whom antibiotics are required for treatment of the bacteremia
  • Immunosuppressed patients
  • AAST Appendicitis Grade V

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Postoperative antibiotics
Patients receive antibiotics following surgery for perforated appendicitis.
Patients receive oral antibiotics following surgery for perforated appendicitis. The dose, duration, and type are at the discretion of the treating physician.
Aktiv komparator: No postoperative antibiotics
Patients do not receive antibiotics following surgery for perforated appendicitis.
Patients do not receive antibiotics following surgery for perforated appendicitis.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Average number of participants enrolled per month across multiple sites.
Tidsramme: First to last day of each month of recruitment phase (1 year).
Assessment of accrual: feasible if 10 or more overall.
First to last day of each month of recruitment phase (1 year).
Percentage of participants who receive the correct intervention.
Tidsramme: From beginning to end of recruitment phase (1 year).
Assessment of ability to accurately deliver the intervention that participants were randomized to receive: feasible if >90% of participants receive the assigned intervention.
From beginning to end of recruitment phase (1 year).
Percentage of patient-reported outcomes collected.
Tidsramme: Duration of the study (1 year). For each participant, data collected 30 and 90 days after surgery.
Assessment of ability to collect complete data for patient reported outcomes. Feasible if >80% of data is collected directly from patients with an additional 10% collected from patient health records.
Duration of the study (1 year). For each participant, data collected 30 and 90 days after surgery.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Quality of Life, as assessed by EQ-5D-5L.
Tidsramme: 30 and 90 days after surgery for perforated appendicitis.
Level Sum Score can be calculated, ranging from 5 to 25, with higher scores representing a worse health status.
30 and 90 days after surgery for perforated appendicitis.
Post-operative pain, as assessed by PROMIS Pain Inventory.
Tidsramme: 30 days after surgery for perforated appendicitis.
5-point Likert scale, with higher scores (i.e., 5 or "very much") indicating higher levels of pain.
30 days after surgery for perforated appendicitis.
Percentage of patients with surgical site infections, as assessed by Participant Assessment of Surgical Wound questionnaire.
Tidsramme: 30 days after surgery for perforated appendicitis.
5 questions (4 yes/no answers, 1 check all that apply).
30 days after surgery for perforated appendicitis.
Percentage of participants prescribed systemic antibiotics.
Tidsramme: Within 30 days after surgery for perforated appendicitis.
Collected from Participant Assessment of Surgical Wound questionnaire or patient health records.
Within 30 days after surgery for perforated appendicitis.
Post-operative complications, as assessed by Health Resource Utilization questionnaire.
Tidsramme: Within 90 days after surgery for perforated appendicitis.
6 questions (5 yes/no, 1 check all that apply).
Within 90 days after surgery for perforated appendicitis.
Healthcare utilization, as assessed by Health Resource Utilization questionnaire.
Tidsramme: Within 90 days after surgery for perforated appendicitis.
Healthcare utilization, including number of: reinterventions, all-cause reoperations, emergency department visits, all-cause unplanned family physician or walk-in clinic visits, and all-cause readmissions and length of stay of each readmission.
Within 90 days after surgery for perforated appendicitis.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. januar 2028

Studiet fullført (Antatt)

1. mai 2028

Datoer for studieregistrering

Først innsendt

1. juni 2026

Først innsendt som oppfylte QC-kriteriene

15. juni 2026

Først lagt ut (Faktiske)

18. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere